Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes

Epilepsia

Volumn 50, Issue 3, 2009, Pages 493-500

  Zachry III, Woodie M ^a   Doan, Quynhchau D ^a   Clewell, Jerry D ^a   Smith, Brien J ^b  

^a ABBOTT LABORATORIES   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

Antiepileptic drugs; Epilepsy; Generic substitution; Switch

Indexed keywords

ANTICONVULSIVE AGENT; GENERIC DRUG; ZONISAMIDE;

ADOLESCENT; ADULT; AMBULANCE; ANTICONVULSANT THERAPY; ARTICLE; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; DRUG FORMULATION; DRUG SUBSTITUTION; EMERGENCY WARD; EPILEPSY; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MEDICAID; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AMBULANCES; ANTICONVULSANTS; CASE-CONTROL STUDIES; COST SAVINGS; DRUG COSTS; DRUGS, GENERIC; EMERGENCY MEDICAL SERVICES; EMERGENCY SERVICE, HOSPITAL; EPILEPSIES, PARTIAL; EPILEPSY, GENERALIZED; FEMALE; HUMANS; ISOXAZOLES; MALE; MEDICAID; MIDDLE AGED; ODDS RATIO; PATIENT ADMISSION; RETROSPECTIVE STUDIES; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 61849112140     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2008.01703.x     Document Type: Article

References (28)

1. AAN 1990) Assessment: generic substitution for antiepileptic medication. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 40 : 1641 1643.
2. Andermann F, Duh MS, Gosselin A, Paradis PE 2007) Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 48 : 464 469.
3. CDER-U.S. Food and Drug Administration Center for Drug Evaluation and Research. http://www.fda.gov/cder/orange/obannual.pdf. Last accessed 12/05/2007.
4. Crawford P, Hall WW, Chappell B, Collings J, Stewart A 1996) Generic prescribing for epilepsy. Is it safe? Seizure 5 : 1 5.
5. Duh MS, Andermann F, Paradis PE, Weiner J, Manjunath R, Cremieux PY 2007) The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine. Dis Manag 10 : 216 225.
6. Forsgren L, Hauser WA, Olafsson E, Sander JW, Sillanpaa M, Tomson T 2005) Mortality of epilepsy in developed countries: a review. Epilepsia 46 (Suppl 11 18 27.
7. Gilman JT, Alvarez LA, Duchowny M 1993) Carbamazepine toxicity resulting from generic substitution. Neurology 43 : 2696 2697.
8. Haskins LS, Tomaszewski KJ, Crawford P 2005) Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy. Epilepsy Behav 7 : 98 105.
9. Karceski S, Morrell MJ, Carpenter D 2005) Treatment of epilepsy in adults: expert opinion. Epilepsy Behav 7 : S1-S64.
10. Koch G, Allen JP 1987) Untoward effects of generic carbamazepine therapy. Arch Neurol 44 : 578 579.
11. Kramer G, Steinhoff BJ, Feucht M, Pfafflin M, May TW 2007) Experience with generic drugs in epilepsy patients: an electronic survey of members of the German, Austrian and Swiss branches of the ILAE. Epilepsia 48 : 609 611.
12. Kumar S 2005) Factors precipitating seizures in well-controlled epilepsy. Indian Pediatr 42 : 182 183.
13. Macdonald JT 1987) Seizure following substitution of Depakene capsules (Abbott) with a generic product. Neurology 37 : 1885.
14. Makus KG, Mccormick J 2007) Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy. Clin Ther 29 : 334 341.
15. Mayer MT, Altenmuller DM, Sandmann M, Wolf P 1999) Clinical problems with generic antiepileptic drugs. Comparison of sustained-release formulations of carbamazepine. Clin Drug Invest 18 : 17 26.
16. National Institute of Neurological Disorders and Stroke, National Institutes of Health. (2004) Seizures and Epilepsy: Hope Through Research. NIH Publication. Published online 1-May-2004; document number: 04-156. Available at http://www.ninds.nih.gov/disorders/epilepsy/detail-epilepsy.htm [Accessed June 10, 2008].
17. Perucca E, Albani F, Capovilla G, Bernardina BD, Michelucci R, Zaccara G 2006) Recommendations of the Italian League against epilepsy working group on generic products of antiepileptic drugs. Epilepsia 47 (Suppl 5 16 20.
18. SANAD Study Group 2007a) The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblended randomized controlled trial. Lancet 369 : 1000 1015.
19. SANAD Study Group 2007b) The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 369 : 1016 1026.
20. Silpakit O, Amornpichetkoon M, Kaojarern S 1997) Comparative study of bioavailability and clinical efficacy of carbamazepine in epileptic patients. Ann Pharmacother 31 : 548 552.
21. Thomas P, Valton L, Genton P 2006) Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy. Brain 129 : 1281 1292.
22. Tyrer JH, Eadie MJ, Sutherland JM, Hooper WD 1970) Outbreak of anticonvulsant intoxication in an Australian city. Br Med J 4 : 271 273.
23. United States Centers For Disease Control And Prevention, Coordinating Center for Health Promotion, U.S. Department of Health and Human Services. (2008) Targeting epilepsy one of the nations most common disabling neurological conditions. At a Glance Reports Published online: 1-January-2008; document number: CS115667. Available at http://www.cdc.gov/nccdphp/publications/AAG/pdf/ epilepsy.pdf [Accessed June 10, 2008].
24. United States Food and Drug Administration, Center for Drug Evaluation and Research, U.S. Department of Health and Human Services. (2008) Approved Drug Products with Therapeutic Equivalence Evaluations, 28th ed. U.S. Department of Health and Human Services, Washington, D.C.
25. Welty TE, Pickering PR, Hale BC, Arazi R 1992) Loss of seizure control associated with generic substitution of carbamazepine. Ann Pharmacother 26 : 775 777.
26. Wilner AN 2002) Physicians underestimate the frequency of generic carbamazepine substitution: results of a survey and review of the problem. Epilepsy Behav 3 : 522 525.
27. Wilner AN 2004) Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav 5 : 995 998.
28. Woodward M 2005) Epidemiology study design and data analysis. 2nd ed. Chapman & Hall/CRC, Boca Raton.